go to contents

PhagoMed Biopharma GmbH

Back to list

Facts

Founded
2017
Staff
13
Organization type
RDM biotech/pharma
Region
Vienna
Cluster
LISAvienna
Focus
human health

Profile

PhagoMed Biopharma GmbH is a pre-clinical biotech company focused on accelerating the re-introduction of phage therapy into Western medical practice. PhagoMed builds on the treatment expertise of its co-founders Prof. Dr. Wippermann and PD Dr. Trampuz, who have jointly treated ~20 patients with bacteriophages as a last resort over the past 15 years. As of early 2018, PhagoMed has completed its seed financing round (private investment

R&D:PhagoMed focuses on bacteriophage applications in areas of high medical need, where antibiotics typically fail. The lead indication is the field of periprosthetic infections, a devastating and hard-to-treat indication. Together with the research partners at Charité in Berlin, PhagoMed has shown that phages act synergistically with antibiotics to kill the biofilm that typically forms in these infections. PhagoMed is also active in the field of Urogenital Infections.

Similar companies in RDM biotech/pharma

Ribbon Biolabs GmbH

Organization type
RDM biotech/pharma
Region
Vienna
Cluster
LISAvienna
Focus
bioinformatics
Details

Richter Pharma AG

Organization type
RDM biotech/pharma
Region
Upper Austria
Focus
human health
Details

Aelian Biotechnology GmbH

Organization type
RDM biotech/pharma
Region
Vienna
Focus
non-specific applications
Details

Biogen Austria GmbH

Organization type
RDM biotech/pharma
Region
Vienna
Cluster
LISAvienna
Focus
human health
Details

Contact

Leberstraße 20
1110 Wien
Vienna

Contact: Alexander Belcredi (Co-Founder | CEO)
Email: contact@phagomed.com
Website